Intra-Cellular Therapies' lumateperone shows significant efficacy in reducing schizophrenia relapse rates, with a 63% risk ...

The study also included an 18-week open-label phase, during which patients with Schizophrenia were treated with Lumateperone 42 mg per day. The biopharmaceutical company found that the time to relapse ...

Some people who took a new schizophrenia drug for one year improved with only a few side effects, but many dropped out of the ...

Bristol Myers Squibb's revenue was fueled by Growth Portfolio and Eliquis. Analysts anticipate an impact from Cobenfy and a ...

Intra-Cellular Therapies’ atypical antipsychotic medication Caplyta has been on a roll, delivering fast commercial growth and coming up triumphant in yet another late-stage trial. | Intra-Cellular ...

044). Conversely, 6 taxa, such as rhodospirillaceae, defluviitaleaceae, and desulfovibrio, were protective against schizophrenia (OR: 0.88-0.94; P ≤.049). The findings may provide evidence for the ...

Data presented at Psych Congress 2024 showed improvements in social functioning and quality of life over an eight-week ...

Art therapy can complement other treatment approaches, such as medication or counseling, offering significant benefits to many individuals with schizophrenia. Family and healthcare professionals ...

Schizophrenia significantly shortens life expectancy by an estimated 15 years with excess mortality arising from multiple ...

The usual age range of a schizophrenia diagnosis is 16 to 30 years old. It’s important to begin treatment for schizophrenia as soon as possible after someone first experiences psychosis.

Bristol Myers Squibb's (BMY) new schizophrenia drug, Cobenfy, improves symptoms with a well-tolerated safety profile in two ...

Leal Therapeutics has secured yet another multi-million financing deal as the Worcester-based biotechnology startup has ...